Key Findings Reviewed From ALCYONE Trial in Myeloma

Dec 04, 2018

Maria-Victoria Mateos, MD, PhD, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib, melphalan, and prednisone in combination with daratumumab in patients with newly diagnosed multiple myeloma who are transplant ineligible.

Maria-Victoria Mateos, MD, PhD, a physician and director of the myeloma program at the University of Salamanca, Spain, discusses the key takeaways from the phase III ALCYONE trial looking at bortezomib (Velcade), melphalan, and prednisone (VMP) in combination with daratumumab (Darzalex; DARA; D-VMP) in patients with newly diagnosed multiple myeloma who are transplant ineligible.

After a median follow-up of 28 months, D-VMP was superior to VMP in terms of overall response rate, complete response rate, and progression-free survival (PFS), Mateos says. PFS acted as a surrogate marker for overall survival.

Related Content